Cymbalta (Duloxetine) Onsite Taper

No. You arrive on your current prescribed duloxetine dose and the taper is done onsite under continuous cardiac telemetry, bridged with sub-psychoactive full-spectrum iboga total alkaloid at 75–150 mg BID. MindScape does not ask you to attempt a solo washout at home before treatment. A small number of other medications — MAOIs, lithium, tricyclic antidepressants, tramadol and certain QT-prolonging cardiac medications — do still need to be cleared before you arrive, so our medical team reviews your full medication list in advance.

Typically 14–24 days onsite. That range is driven by duloxetine's intermediate half-life — ≈ 12 hours — and your baseline dose, usually 20–120 mg/day. Reductions are hyperbolic rather than linear, so the schedule follows how you actually respond instead of running to a fixed calendar.

The duloxetine discontinuation profile covers: Brain zaps and electric-shock sensations; Dizziness and gait instability; Noradrenergic rebound — sweating, BP elevation; Anxiety crises, irritability; Sleep disruption, vivid dreams. The onsite protocol bridges the taper with sub-psychoactive iboga total alkaloid (75–150 mg BID) to cover the receptor-occupancy gap as your dose comes down, with symptom-driven support and continuous monitoring throughout.

Capsule-bead formulation makes accurate micro-tapering at home almost impossible. Both serotonergic and noradrenergic components — same receptor breadth challenge as venlafaxine. Discontinuation syndrome frequently mistaken for chronic-pain relapse (duloxetine is also indicated for fibromyalgia and neuropathic pain).

Yes. Capsule-bead counting or compounded preparation for hyperbolic taper. Iboga TA bridge 75–150 mg BID covering both 5-HT and noradrenergic withdrawal. Continuous telemetry with BP and HR monitoring. Symptom-driven adjuncts: magnesium, hydroxyzine, ondansetron.

A flood dose of ibogaine HCl is only administered once duloxetine has been reduced to a protocol-defined safe threshold and your cardiac screening is still within limits — eligibility is confirmed at that point rather than promised in advance. Ibogaine is an investigational compound, is not approved by the FDA, and results vary between patients. If your medication picture or your screening makes treatment unsafe, we will tell you honestly.